mRNA challenge predicts brain cancer immunogenicity and response to checkpoint inhibitors.
mRNA challenge predicts brain cancer immunogenicity and response to checkpoint inhibitors.
复制标题
mRNA 挑战可预测脑癌免疫原性和对检查点抑制剂的反应。
DOI：
10.1101/2023.03.18.532056
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
Silver
中科院分区：
文献类型：
--
作者：
Castillo,Paul;Ogando-Rivas,Elizabeth;Geffrard,Hilary;Pepe,Alfonso;Liu,Ruixuan;Nguyen,DuyT;Pedro,DiegoI;Zhang,Dingpeng;DeVries,Anna;Qdaisat,Sadeem;Karachi,Aida;Rahman,Maryam;Weidert,Frances;Milner,Rowan;Huang,Jianping;Silver
为了前瞻性地确定脑肿瘤是否会对免疫检查点抑制剂（ICI）产生反应，我们开发了一种新型mRNA疫苗作为病毒模拟物，以阐明体外脑癌细胞释放的细胞因子。我们的研究结果表明，细胞因子的签名后，mRNA的挑战有很大的不同ICI响应与非响应小鼠肿瘤。这些发现允许创建诊断测定以快速评估脑肿瘤免疫原性，允许在免疫原性差的情况下使用ICI或缺乏ICI进行知情治疗。
To prospectively determine whether brain tumors will respond to immune checkpoint inhibitors (ICIs), we developed a novel mRNA vaccine as a viral mimic to elucidate cytokine release from brain cancer cells in vitro. Our results indicate that cytokine signatures following mRNA challenge differ substantially from ICI responsive versus non-responsive murine tumors. These findings allow for creation of a diagnostic assay to quickly assess brain tumor immunogenicity, allowing for informed treatment with ICI or lack thereof in poorly immunogenic settings.